The Discovery Rule: Fairness in Toxic Tort Statutes of Limitations

The costs associated with the disposal of toxic waste can be classified in two ways. The first category is made up of environmental losses such as the contamination of rivers, lakes, and ground water with the resulting destruction of aquatic life, wildlife, and vegetation and includes expenses incurred in cleanup. The second category is comprised of losses sustained by individuals and includes both property damage and physical injury resulting from direct or indirect contact with hazardous wastes. Injured individuals have two options in their pursuit of compensation: statutory and common law. This Article argues that statutory recourse is not only inadequate but also often precludes common law means of redress. The first section addresses the shortcomings of third-party restitution under past and present legislation. The remaining sections outline the problems and inequities of statutes of limitations in the adjudication of hazardous waste torts

The Discovery Rule: Fairness in Toxic Tort Statutes of Limitations

The costs associated with the disposal of toxic waste can be classified in two ways. The first category is made up of environmental losses such as the contamination of rivers, lakes, and ground water with the resulting destruction of aquatic life, wildlife, and vegetation and includes expenses incurred in cleanup. The second category is comprised of losses sustained by individuals and includes both property damage and physical injury resulting from direct or indirect contact with hazardous wastes. Injured individuals have two options in their pursuit of compensation: statutory and common law. This Article argues that statutory recourse is not only inadequate but also often precludes common law means of redress. The first section addresses the shortcomings of third-party restitution under past and present legislation. The remaining sections outline the problems and inequities of statutes of limitations in the adjudication of hazardous waste torts

The Discovery Rule: Fairness in Toxic Tort Statutes of Limitations

The costs associated with the disposal of toxic waste can be classified in two ways. The first category is made up of environmental losses such as the contamination of rivers, lakes, and ground water with the resulting destruction of aquatic life, wildlife, and vegetation and includes expenses incurred in cleanup. The second category is comprised of losses sustained by individuals and includes both property damage and physical injury resulting from direct or indirect contact with hazardous wastes. Injured individuals have two options in their pursuit of compensation: statutory and common law. This Article argues that statutory recourse is not only inadequate but also often precludes common law means of redress. The first section addresses the shortcomings of third-party restitution under past and present legislation. The remaining sections outline the problems and inequities of statutes of limitations in the adjudication of hazardous waste torts

The Discovery Rule: Fairness in Toxic Tort Statutes of Limitations

The costs associated with the disposal of toxic waste can be classified in two ways. The first category is made up of environmental losses such as the contamination of rivers, lakes, and ground water with the resulting destruction of aquatic life, wildlife, and vegetation and includes expenses incurred in cleanup. The second category is comprised of losses sustained by individuals and includes both property damage and physical injury resulting from direct or indirect contact with hazardous wastes. Injured individuals have two options in their pursuit of compensation: statutory and common law. This Article argues that statutory recourse is not only inadequate but also often precludes common law means of redress. The first section addresses the shortcomings of third-party restitution under past and present legislation. The remaining sections outline the problems and inequities of statutes of limitations in the adjudication of hazardous waste torts

Primary neurons that express the L2/HNK-1 carbohydrate during early development in the zebrafish

In zebrafish, many nerve pathways in both the CNS and periphery are pioneered by a small and relatively simple set of ‘primary’ neurons that arise in the early embryo. We now have used monoclonal antibodies to show that, as they develop, primary neurons of several functional classes express on their surfaces the L2/HNK-1 tetrasaccharide that is associated with a variety of cell surface adhesion molecules. We have studied the early labeling patterns of these neurons, as well as some non-neural cells, and found that the time of onset and intensity of immunolabeling vary specifically according to cell type. The first neuronal expression is by Rohon-Beard and trigeminal ganglion neurons, both of which are primary sensory neurons that mediate touch sensitivity. These cells express the epitope very strongly on their growth cones and axons, permitting study of their development unobscured by labeling in other cells. Both types initiate axogenesis at the same early time, and appear to be the first neurons in the embryo to do so. Their peripheral neurites display similar branching patterns and have similar distinctive growth cone morphologies. Their central axons grow at the same rate along the same longitudinal fiber pathway, but in opposite directions, and where they meet they appear to fasciculate with one another. The similarities suggest that Rohon-Beard and trigeminal ganglion neurons, despite their different positions, share a common program of early development. Immunolabeling is also specifically present on a region of the brain surface where the newly arriving trigeminal sensory axons will enter the brain. Further, the trigeminal expression of the antigen persists in growth cones during the time that they contact an individually identified central target neuron, the Mauthner cell, which also expresses the epitope. These findings provide descriptive evidence for possible roles of L2/HNK-1 immunoreactive molecules in axonal growth and synaptogenesis

The Spitzer c2d Survey of Nearby Dense Cores: III: Low Mass Star Formation in a Small Group, L1251B

We present a comprehensive study of a low-mass star-forming region,L1251B, at wavelengths from the near-infrared to the millimeter. L1251B, where only one protostar, IRAS 22376+7455, was known previously, is confirmed to be a small group of protostars based on observations with the Spitzer Space Telescope. The most luminous source of L1251B is located 5" north of the IRAS position. A near-infrared bipolar nebula, which is not associated with the brightest object and is located at the southeast corner of L1251B, has been detected in the IRAC bands. OVRO and SMA interferometric observations indicate that the brightest source and the bipolar nebula source in the IRAC bands are deeply embedded disk sources.Submillimeter continuum observations with single-dish telescopes and the SMA interferometric observations suggest two possible prestellar objects with very high column densities. Outside of the small group, many young stellar object candidates have been detected over a larger region of 12' x 12'. Extended emission to the east of L1251B has been detected at 850 micron; this "east core" may be a site for future star formation since no point source has been detected with IRAC or MIPS. This region is therefore a possible example of low-mass cluster formation, where a small group of pre- and protostellar objects (L1251B) is currently forming, alongside a large starless core (the east core).Comment: 35 pages, 15 figures, accepted for publication in ApJ, for the full resolution paper, visit "http://peggysue.as.utexas.edu/SIRTF/PAPERS/pap27.pub.pdf

From diagnosis of colorectal cancer to diagnosis of Lynch syndrome: The RM Partners quality improvement project.

AIM: The UK National Institute for Health and Care Excellence guideline DG27 recommends universal testing for Lynch syndrome (LS) in all newly diagnosed colorectal cancer (CRC) patients. However, DG27 guideline implementation varies significantly by geography. This quality improvement project (QIP) was developed to measure variation and deliver an effective diagnostic pathway from diagnosis of CRC to diagnosis of LS within the RM Partners (RMP) West London cancer alliance. METHOD: RM Partners includes a population of 4 million people and incorporates nine CRC multidisciplinary teams (MDTs), overseen by a Pathway Group, and three regional genetic services, managing approximately 1500 new CRC cases annually. A responsible LS champion was nominated within each MDT. A regional project manager and nurse practitioner were appointed to support the LS champions, to develop online training packages and patient consultation workshops. MDTs were supported to develop an 'in-house' mainstreaming service to offer genetic testing in their routine oncology clinics. Baseline data were collected through completion of the LS pathway audit of the testing pathway in 30 consecutive CRC patients from each CRC MDT, with measurement of each step of the testing pathway. Areas for improvement in each MDT were identified, delivered by the local champion and supported by the project team. RESULTS: Overall, QIP measurables improved following the intervention. The Wilcoxon signed rank test revealed significant differences with strong effect sizes on the percentile of CRC cases undergoing mismatch repair (MMR) testing in endoscopic biopsies (p = 0.008), further testing with either methylation or BRAF V600E (p = 0/03) and in effective referral for genetic testing (from 10% to 74%; p = 0.02). During the QIP new mainstreaming services were developed, alongside the implementation of systematic and robust testing pathways. These pathways were tailored to the needs of each CRC team to ensure that patients with a diagnosis of CRC had access to testing for LS. Online training packages were produced which remain freely accessible for CRC teams across the UK. CONCLUSION: The LS project was completed by April 2022. We have implemented a systematic approach with workforce transformation to facilitate identification and 'mainstreamed' genetic diagnosis of LS. This work has contributed to the development of a National LS Transformation Project in England which recommends local leadership within cancer teams to ensure delivery of diagnosis of LS and integration of genomics into clinical practice

Stepping out of Flatland: Discovering Behavior Patterns as Topological Structures in Cyber Hypergraphs

Data breaches and ransomware attacks occur so often that they have become part of our daily news cycle. This is due to a myriad of factors, including the increasing number of internet-of-things devices, shift to remote work during the pandemic, and advancement in adversarial techniques, which all contribute to the increase in both the complexity of data captured and the challenge of protecting our networks. At the same time, cyber research has made strides, leveraging advances in machine learning and natural language processing to focus on identifying sophisticated attacks that are known to evade conventional measures. While successful, the shortcomings of these methods, particularly the lack of interpretability, are inherent and difficult to overcome. Consequently, there is an ever-increasing need to develop new tools for analyzing cyber data to enable more effective attack detection. In this paper, we present a novel framework based in the theory of hypergraphs and topology to understand data from cyber networks through topological signatures, which are both flexible and can be traced back to the log data. While our approach's mathematical grounding requires some technical development, this pays off in interpretability, which we will demonstrate with concrete examples in a large-scale cyber network dataset. These examples are an introduction to the broader possibilities that lie ahead; our goal is to demonstrate the value of applying methods from the burgeoning fields of hypernetwork science and applied topology to understand relationships among behaviors in cyber data.Comment: 18 pages, 11 figures. This paper is written for a general audienc

Development of a Multiplex Real-Time PCR Assay for the detection of ruminant DNA

The U.S. Food and Drug Administration (FDA) has previously validated a real-time PCR-based assay that is currently being used by the FDA and several state laboratories as the official screening method. Due to several shortcomings to the assay, a multiplex real-time PCR assay (MRTA) to detect three ruminant species (bovine, caprine, and ovine) was developed using a lyophilized bead design. The assay contained two primer or probe sets: a "ruminant" set to detect bovine-, caprine-, and ovine-derived materials and a second set to serve as an internal PCR control, formatted using a lyophilized bead design. Performance of the assay was evaluated against stringent acceptance criteria developed by the FDA's Center for Veterinary Medicine's Office of Research. The MRTA for the detection of ruminant DNA passed the stringent acceptance criteria for specificity, sensitivity, and selectivity. The assay met sensitivity and reproducibility requirements by detecting 30 of 30 complete feed samples fortified with meals at 0.1 % (wt/wt) rendered material from each of the three ruminant species. The MRTA demonstrated 100 % selectivity (0.0 % false positives) for negative controls throughout the assessment period. The assay showed ruggedness in both sample selection and reagent preparation. Second and third analyst trials confirmed the quality of the written standard operating procedure with consistency of results. An external laboratory participating in a peer-verification trial demonstrated 100 % specificity in identifying bovine meat and bone meal, while exhibiting a 0.03 % rate of false positives. The assay demonstrated equal levels of sensitivity and reproducibility compared with the FDA's current validated real-time PCR assay. The assay detected three prohibited species in less than 1.5 h of total assay time, a significant improvement over the current real-time assay. These results demonstrated this assay's suitability for routine regulatory use both as a primary screening tool and as a confirmatory test